Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

endometriozei confirmate histologic.

Tratamentul pubertăţii precoce.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
L02AE04 TRIPTORELINUM LIOF. + SOLV. PT. 0.1 mg

SOL. INJ.

DIPHERELINE 0,1 mg 0.1 mg BEAUFOUR IPSEN PHARMA
L02AE04 TRIPTORELINUM LIOF. + SOLV. PT. SUSP. 11.25 mg

INJ. I.M. ELIB. PREL

DIPHERELINE(R) 11,25 mg 11.25 mg BEAUFOUR IPSEN PHARMA
L02AE04 TRIPTORELINUM LIOF. +SOLV. PT. SUSP. 3.75 mg

INJ. I.M. ELIB. PREL.

DIPHERELINE(R) 3,75 mg 3.75 mg BEAUFOUR IPSEN PHARMA

________________________________________________________________________________

______________________________________________________________________________

| 306 |L04AX01| AZATHIOPRINUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
______________________________________________________________________________

| 307 |M01AC01| PIROXICAMUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________
A se administra cu precauţie la pacienţii cu istoric de factori de risc sau afecţiuni gastrointestinale.